Intervention Of Ligustrazin On MDA,iNOS And NO Levels Of The Lung Tissue In Rats With BLM-induced Pulmonary Fibrosis (Case Analysis Of15IPF Patients Was Appended)

Part1Intervention of Ligustrazin on MDA,iNOS and NO Levels ofthe Lung Tissue in Rats with BLM-induced PulmonaryFibrosisObjective:To explore the intervention of Ligustrazin on the rats model of pulmonaryfibrosis induced by BLM and further clarify the part of its anti-fibrotic mechanism.Methods:30SD rats were randomly divided into normal control group,BLM-inducedpulmonary fibrosis group(fibrosis group) and Ligustrazin group,each of group had10rats.By injecting BLM via trachea(5mg kg-1once) to fibrosis group and Ligustrazingroup to establish the pulmonary fibrosis models in rats, while injecting isopyknicnormal saline via trachea to normal control group.From the2nd day after injection, therats in Ligustrazin group were intraperitoneally injected with Ligustrazin(20mg·kg-1·d-1),while the rats in other two groups with isopyknic normal salineinstead.On the28th day,all rats were executed,their left lung lobe tissues were removedand used for pathological section examination by HE staining and Masson triplestaining.and the same time,their right lung lobe tissues were removed to measure thelevels of malonaldehyde(MDA) and inducible nitric oxide synthase(iNOS) and nitricoxide(NO).Results: Detecting by light microscopy,the pulmonary tissue of the rats in normalcontrol group was normal,both fibrosis group and Ligustrazin group appeared fibrotic changes.Compared with fibrosis group,the degree of fibrotic changes in Ligustrazingroup was significantly lighter. Compared with normal control group,the levels ofMDA,iNOS and NO of the lung tissue in rats came from fibrosis group weresignificantly increased(P<0.01),and the MDA,iNOS and NO levels of the rats inLigustrazin group were increased(P<0.05or P<0.01). Compared with fibrosis group,the MDA,iNOS and NO levels of the lung tissue in rats came from Ligustrazin groupwere reduced (P<0.05or P<0.01).Conclusion: The part of mechanism of which Ligustrazin can alleviate pulmonaryfibrosis is reducing the levels of MDA,iNOS and NO in the lung tissue of the rats withpulmonary fibrosis induced by BLM. Part2CaseAnalysis of15IPF PatientsObjective: To explore the clinical characteristics, diagnosis and treatment methods ofthe patients with IPF.Methods: To have a retrospective study on general data,clinicalcharacteristics,laboratory examination,HRCT findings,pulmonary functiontests,treatment and prognosis of15cases of IPF, which were all diagnosed in theDepartment of Respiratory,First Hospital of Dalian Medical University betweenJuly.2011and Jan.2014.Results: Progressive exertional dyspnea was occurred in93.3%of patients,and drycough in all patients. Velcro rales from both of lungs were heard in all patients.20%ofpatients had the clubbed fingers. Arterial blood gas analysis was examined in allpatients,which indicated hypoxemia and type I orⅡrespiratory failure in part of thepatients. HRCT was examined in all patients, which showed the below-pleurallesions,while reticular shadow and honeycombing changes were presented in all the patients’ image data. Pulmonary function tests showed the limitation ventilationdysfunction and/or diffusion dysfunction.80%of patients need to received oxygentherapy to improve hypoxemia.93.3%of patients had received the treatment of oral N-acetyl cysteine (NAC), dyspnea was improved in63.3%of them,and dry cough wasrelieved in35.7%of these patients.There are3patients had received the therapy ofprednisone on the basis of oral NAC, dyspnea of which1patients was significantlyimproved after the combination.Conclusion: Exertional dyspnea and other clinical features are important clues toclinical diagnosis, HRCT findings is the important basis of definite diagnosis.